Trials / Completed
CompletedNCT02005198
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 98 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 23 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted in the United States of America (USA). The aim of the study is to assess the minimal important difference (MID) of the TRIM-AGHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No treatment given | Subject will only fill out a questionnaire when entering the non-interventional study |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2013-12-09
- Last updated
- 2017-01-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02005198. Inclusion in this directory is not an endorsement.